Summary: Researchers have identified an alternative gut-driven pathway that explains how GLP-1 receptor agonists can reduce psychiatric symptoms. Using chronic-stress mouse models, the team tracked the psychiatric effects of liraglutide, a GLP-1 analog commonly used for weight loss and type 2 diabetes, and discovered a microbiome–endocannabinoid mechanism linking the intestine to mood regulation.
The study found that liraglutide concentrates in the intestine rather than the brain. In the gut it promotes a striking expansion of the bacterium Lactobacillus delbrueckii. This microbe produces diacylglycerol, a precursor that the host converts into the endocannabinoid 2-arachidonoylglycerol (2-AG). Increased 2-AG levels act on stress-related neural circuits to reduce hyperactivity and normalize depressive-like behaviors in mice.
Key Facts
- Challenges the brain-centric model: Prior explanations for antidepressant or mood-related effects of GLP-1 drugs assumed the compounds acted directly in the central nervous system. This study offers clear evidence for a peripheral, gut-mediated mechanism.
- Intestinal accumulation over brain penetration: Liraglutide administered systemically was shown to accumulate primarily in intestinal tissue rather than crossing into the brain.
- Receptor knockout validation: Genetically modified mice lacking GLP-1 receptors (Glp1r−/−) still experienced antidepressant and anti-anxiety effects from liraglutide, demonstrating the response does not require direct GLP-1R engagement in the brain.
- Microbiome dependence: Broad-spectrum antibiotics that depleted gut microbes abolished liraglutide’s behavioral benefits, confirming a requirement for live gut bacteria.
- Rise of Lactobacillus delbrueckii: Metagenomic analysis of fecal samples identified L. delbrueckii as the most substantially increased species following treatment, and its abundance correlated with behavioral improvements.
- Endocannabinoid pathway: L. delbrueckii produces diacylglycerol, which the host converts to the endocannabinoid 2-AG. Elevated 2-AG levels were linked to reduced neuronal hyperactivity in emotional processing regions of the brain.
- Therapeutic potential: The findings suggest targeted probiotic strategies—specifically high-potency strains of L. delbrueckii—could one day be developed as adjunct or alternative treatments to address depression in people with metabolic conditions.
- Study limitations: Experiments were performed in male mouse models only. The authors emphasize the need for female subjects and human clinical trials to determine whether the same microbiome–endocannabinoid pathway operates across sexes and translates to patients.
Source: Cell Press
Overview
Clinical reports have been mixed about whether GLP-1 receptor agonists provide psychiatric benefits. Some trials and observational studies reported reductions in depressive symptoms among people taking GLP-1 drugs, while others raised concerns about mood changes. To clarify the mechanism, researchers at Southeast University used the GLP-1 analog liraglutide in chronic-stress mouse models and combined behavioral testing with pharmacology, genetics, microbiome profiling, and metabolomics.
Co-corresponding authors Yonggui Yuan, Bing Han, and Honghong Yao report that liraglutide’s mood-improving effects did not require direct action on central GLP-1 receptors. Instead, liraglutide accumulated in intestinal tissues and reshaped the gut microbiome. When gut bacteria were depleted by antibiotics, the antidepressant-like effects disappeared, indicating the microbiome is essential for the behavioral outcomes.
Detailed fecal metagenomics highlighted Lactobacillus delbrueckii as the species most strongly enriched by liraglutide treatment. Metabolic analysis showed increased levels of diacylglycerol linked to this bacterium, and host tissues converted that lipid into 2-AG, an endogenous endocannabinoid. Elevated 2-AG then dampened excessive neuronal activity in brain regions involved in stress and emotional processing, producing measurable reductions in depressive- and anxiety-like behaviors in mice.
The authors validated causality by transferring fecal microbiota from liraglutide-treated mice into stressed, untreated recipients; the recipients displayed similar behavioral improvements. Colonizing mice with L. delbrueckii alone also reproduced the antidepressant-like effects, strengthening the case that a specific microbe-driven metabolic pathway mediates the response.
Key Questions Answered:
A: By reshaping the gut microbiome. Liraglutide concentrates in the intestine and promotes the growth of Lactobacillus delbrueckii, which triggers a biochemical cascade that increases the host’s production of the endocannabinoid 2-AG. That signal modulates stress-related brain circuits from the periphery.
A: The endocannabinoid 2-AG. L. delbrueckii produces diacylglycerol, a lipid precursor converted by the host into 2-AG. Higher 2-AG levels act on neural circuits to reduce hyperactivity associated with anxiety and depression.
A: No. These results come from controlled animal experiments. Human clinical trials are needed before changing treatment recommendations. The study does, however, support future research into targeted probiotics or microbiome-based therapies that mimic the beneficial gut–brain signaling identified here.
Editorial Notes:
- Edited by a Neuroscience News editor.
- Journal paper reviewed in full.
- Additional context added by staff.
About this neuropharmacology and depression research news
Author: Julia Grimmett
Source: Cell Press
Contact: Julia Grimmett – Cell Press
Image: The image is credited to Neuroscience News
Original Research: Microbiota-driven gut–brain signaling underlies antidepressant effects of a GLP-1 analog. Liang Bian, Yang Cai, Yuan Zhang, Ling Shen, Huijuan Wang, Feng Gao, Ningbo Cai, Wenbo Chen, Conghui You, Yurui Yang, Fang Wang, Yonggui Yuan, Bing Han, and Honghong Yao. Cell Host & Microbe. DOI: 10.1016/j.chom.2026.05.003. Open access.
Abstract
Microbiota-driven gut–brain signaling underlies antidepressant effects of a GLP-1 analog
GLP-1 receptor agonists are widely used to treat metabolic disease, yet their neuropsychiatric effects remain controversial. This study demonstrates that liraglutide reduces depressive behaviors through a GLP-1R–independent gut–brain pathway. Using pharmacological blockade and Glp1r−/− mice, the researchers showed liraglutide retained antidepressant efficacy, whereas depletion of the gut microbiota abolished its effects. Multi-omics analyses indicated that liraglutide markedly increased Lactobacillus delbrueckii abundance, restoring host levels of the endocannabinoid 2-arachidonoylglycerol (2-AG). Elevated 2-AG normalized excessive neuronal activity in emotional brain regions and mediated antidepressant outcomes. Fecal microbiota transplantation from liraglutide-treated mice or colonization with L. delbrueckii replicated the behavioral benefits. These results reveal a microbiota–endocannabinoid metabolic pathway as a potential target for treating depression linked to metabolic disorders.
Funding: Supported by grants from the Science and Technology Innovation 2030–Major Project of the Ministry of Science and Technology of China, the National Natural Science Foundation of Distinguished Young Scholars and other national and provincial funding bodies, the Fundamental and Interdisciplinary Disciplines Breakthrough Plan of the Ministry of Education of China, and institutional research funds.